胸腺五肽治疗慢性重型乙型病毒性肝炎的疗效评价

Evaluation of the therapeutic effect of thymopentin in the treatment of chronic severe viral hepatitis B

目的 评价胸腺五肽治疗慢性重型乙型肝炎的临床疗效。方法 将 70例慢性重型乙型肝炎患者按入院先后分为 2组 ,其中一组 3 5例患者仅用常规内科支持治疗 ,另一组 3 5例患者在常规内科支持治疗基础上加用胸腺五肽 ,比较两组患者治疗后肝功能状况与外周血CD4+ /CD8+ 比值及其存活率。结果 在重型肝炎早中期患者 ,胸腺五肽治疗组的存活率( 66.7%)显著高于对照组 ( 3 3 .3 %) ,P <0 .0 5 ;胸腺五肽治疗 2周后 ,40 0 %患者的肝功能开始好转 ,对照组肝功能开始好转者只有 10 .0 %,两者间相差显著 (P <0 0 5 ) ;与治疗前相比 ,胸腺五肽治疗组重型肝炎患者在治疗 2周与 4周后的外周血CD4+ /CD8+ 比值均增高非常显著 (P <0 0 1) ,且均显著高于对照组患者 (P <0 0 1) ;治疗 2周时重型肝炎患者外周血CD4+ /CD8+ 比值越大 ,其最终存活率也越高。

Objective To evaluate the clinical effect of thymopentin in the treatment of chronic severe viral hepatitis B(CSHB). Methods A total of 70 patients with CSHB were divided into two groups. Patients in the control group( n =35) received only routine medicine support therapies. Patients in treatment group( n =35) received thymopentin treatment on the basis of routine medicine support therapies. The differences in the survival rate, liver function and the ratio of CD4 +/CD8 + cells of patients with CSHB in the control group and the thymopentin group were compared. Results The survival rate of patients with CSHB at the early and middle stages in thymopentin group(66 7%) was significantly higher than that in the control group(33 3%)( P <0 05). The percentage of patients whose liver functions began to improve was significantly higher in the thymopentin group(40 0%) than that in the control group(10 0%) after 2 weeks of treatment( P <0 05). The ratio of CD4 +/CD8 + cells in thymopentin group after 2 and 4 weeks of thymopentin treatment was significantly higher than that before treatment( P <0 01) and that in the control group at the same time points( P <0 01). The final survival rate was dependent on the ratio of CD4 +/CD8 + cells after 2 weeks of treatment. Conclusion Thymopentin treatment may be beneficial to improving the prognosis of the patients with CSHB at the early stage and middle stages.